Pembrolizumab for Salivary Gland Cancer

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Salivary Gland CancerPembrolizumab - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new treatment for salivary gland cancer that has spread or come back and is not able to be treated with surgery or radiation.

Eligible Conditions
  • Salivary Gland Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 5 Secondary · Reporting Duration: 35 months

12 Months
Overall Survival
Progression Free Survival
35 Months
Disease Control Rate
35 months
Assess Adverse Events
Number of participants with grade 3, 4, 5 adverse events
Objective Response Rate

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Side Effects for

Pembrolizumab Second Course
100%Parkinsonism
100%Urinary tract infection
100%Inappropriate antidiuretic hormone secretion
This histogram enumerates side effects from a completed 2021 Phase 3 trial (NCT03066778) in the Pembrolizumab Second Course ARM group. Side effects include: Parkinsonism with 100%, Urinary tract infection with 100%, Inappropriate antidiuretic hormone secretion with 100%.

Trial Design

1 Treatment Group

Goserelin Acetate + Pembrolizumab
1 of 1

Experimental Treatment

20 Total Participants · 1 Treatment Group

Primary Treatment: Pembrolizumab · No Placebo Group · Phase 2

Goserelin Acetate + PembrolizumabExperimental Group · 2 Interventions: Goserelin Acetate, Pembrolizumab · Intervention Types: Drug, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Goserelin
FDA approved
Pembrolizumab
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 35 months

Who is running the clinical trial?

Merck Sharp & Dohme LLCIndustry Sponsor
3,681 Previous Clinical Trials
4,957,432 Total Patients Enrolled
TerSera Therapeutics LLCIndustry Sponsor
8 Previous Clinical Trials
1,056 Total Patients Enrolled
Manish PatelLead Sponsor
Manish Patel, MD3.526 ReviewsPrincipal Investigator - University of Minnesota
Big Ten Cancer Research Consortium
1 Previous Clinical Trials
180 Total Patients Enrolled
5Patient Review
Dr. Patel gave me back the ability to do something I love — play the piano — which I didn't think would be possible after my wrist/forearm fracture. He was kind, his staff was great, and he made sure I had everything I needed for a successful recovery.

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Patients must have been treated with prior therapy.
You have salivary gland carcinoma that is not amenable to curative surgery or radiation.
You are not able to perform the tasks required for this study.
You have received prior chemotherapy, radiation, or surgery as part of curative intent therapy.
You have not had prior cancer treatment.